S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Denali TherapeuticsFate TherapeuticsRegenxbioAudentes TherapeuticsAcceleron Pharma
SymbolNASDAQ:DNLINASDAQ:FATENASDAQ:RGNXNASDAQ:BOLDNASDAQ:XLRN
Price Information
Current Price$24.77$29.36$53.72$59.97$94.85
52 Week RangeBuyBuyBuyHoldBuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$29.57$26.63$77.50$50.54$94.31
% Upside from Price Target19.38% upside-9.32% downside44.27% upside-15.73% downside-0.57% downside
Trade Information
Market Cap$2.49 billion$2.19 billion$1.99 billion$2.77 billion$5.01 billion
Beta2.051.950.832.181.17
Average Volume786,146873,817426,9301,504,389807,834
Sales & Book Value
Annual Revenue$129.16 million$4.74 million$218.51 millionN/A$13.99 million
Price / Sales18.42468.239.05N/A359.89
CashflowN/AN/A$2.58 per shareN/AN/A
Price / CashN/AN/A20.81N/AN/A
Book Value$5.76 per share$2.48 per share$14.20 per share($7.48) per share$6.32 per share
Price / Book4.3011.843.78N/A15.01
Profitability
Net Income$-36,240,000.00$-66,600,000.00$99.94 million$-128,820,000.00$-118,870,000.00
EPS($0.39)($1.19)$2.38($3.40)($2.59)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-44.73%-900.24%-99.57%N/A-353.57%
Return on Equity (ROE)-13.37%-48.94%-18.74%N/A-30.79%
Return on Assets (ROA)-10.24%-35.27%-17.47%-38.00%-27.96%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.16%0.10%0.01%N/A0.05%
Current Ratio10.59%7.53%11.49%12.80%14.02%
Quick Ratio10.59%7.53%11.49%12.79%14.02%
Ownership Information
Institutional Ownership Percentage72.98%96.95%78.05%96.33%95.03%
Insider Ownership Percentage21.20%23.19%13.80%5.30%2.50%
Miscellaneous
Employees179104192207173
Shares Outstanding96.03 million75.59 million36.81 million46.27 million53.08 million
Next Earnings Date3/10/2020 (Estimated)3/3/2020 (Estimated)2/26/2020 (Confirmed)2/26/2020 (Estimated)2/27/2020 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel